We can’t show the full text here under this license. Use the link below to read it at the source.
Randomised clinical trial: semaglutide versus placebo reduced liver steatosis but not liver stiffness in subjects with non‐alcoholic fatty liver disease assessed by magnetic resonance imaging
Semaglutide reduces liver fat but not liver stiffness in people with non-alcoholic fatty liver disease
AI simplified
Abstract
Sixty-seven subjects were randomized to receive either once-daily subcutaneous semaglutide 0.4 mg or placebo.
- Change in liver stiffness at week 48 was not significantly different between semaglutide and placebo.
- Significant reductions in liver fat were observed with semaglutide compared to placebo at weeks 24, 48, and 72.
- More subjects achieved a ≥30% reduction in liver fat content with semaglutide versus placebo at all measured time points.
- Decreases in liver enzymes, body weight, and HbA1c were also noted with semaglutide treatment.
AI simplified
Key numbers
0.50
Decrease in Liver Steatosis
Estimated treatment ratio for semaglutide vs. placebo
73.5%
Proportion Achieving ≥30% Reduction
Percentage of subjects achieving this reduction at weeks 48 and 72
-9.68%
Body Weight Change
Estimated treatment difference in body weight at week 72